STIVARGA® is an oral multikinase inhibitor. In a study published in the January 2013 issue of THE LANCET, treatment with STIRVAGA® in patient population resistant or refractory to GLEEVEC® and SUTENT® resulted in significant improvement in progression free survival. This is the third agent approved by the FDA for advanced GIST. As patients with advanced GIST live longer, newer agents with unique mechanism of action will take center stage.
Bottom Ad
Advertisement
Subscribe
